Patients who have had systemic (chemotherapy, biologic therapy or radiotherapy) within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study
Patients who have had chemotherapy, immunotherapy, or investigational therapy, within  weeks ( weeks for nitrosoureas or mitomycin C), or palliative radiotherapy within  weeks prior to the first dose of the study drug
Patients must not have received nitrosoureas or mitomycin-C within  days prior to sub-study registration
Prior chemotherapy is allowed, including platinum therapy; patients must not have received chemotherapy for  weeks prior to the initiation of study treatment and must have recovery =< grade  from any adverse events from any prior chemotherapy (other than alopecia); patients must not have had nitrosoureas or mitomycin C for  weeks prior to the initiation of study treatment
Receipt of cytotoxic chemotherapy within  weeks ( weeks for nitrosoureas and mitomycin C) of scheduled CD dosing.
Treatment with radiation therapy, surgery, chemotherapy, or investigational therapy within one month prior to study entry ( weeks for nitrosoureas or Mitomycin C).
Patients who have had chemotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study
Systemic anticancer therapy within three weeks of study entry, except for nitrosoureas or mitomycin C within six weeks.
Mitomycin C/nitrosoureas less than or equal to  weeks prior to registration
Treatment with surgery or chemotherapy within  days prior to study entry ( days for nitrosoureas or mitomycin C)
Participants who have had chemotherapy, biologic therapy, investigational agents, radiotherapy, or major surgery within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study
ENROLLMENT TO THE DOSE ESCALATION, EXPANSION AND PART II: Participants who have had chemotherapy, radiotherapy, or major surgery within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study
Participants who have had chemotherapy, radiotherapy, biologic therapy, major surgery, or another investigational agent within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study; patients who have received prior PARP inhibitor will not be excluded; patients who have received prior CHK inhibitor will be excluded
Patients who have had radiotherapy (except for palliative reasons), immunotherapy or chemotherapy during the previous  weeks ( weeks for nitrosoureas or mitomycin) before treatment, or those who have ongoing toxic manifestations of previous treatments, with the exception of alopecia, of grade higher than 
Participants who have had chemotherapy, immune therapy, other investigational therapy, major surgery, or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study
The patient has received chemotherapy or radiotherapy within  weeks or has received nitrosoureas or mitomycin C within  weeks prior to the first dose of study drug.
At least three weeks since the last anticancer therapy, including investigational drugs and radiotherapy, and at least six weeks since nitrosoureas and mitomycin C(systemic).
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study
treatment with cytotoxic agents, or treatment with biologic agents within  weeks prior to treatment with APSF ( weeks for mitomycin C or nitrosoureas).
Patients who have had chemotherapy or radiotherapy within  weeks or five half-lives whichever is shorter ( weeks for nitrosoureas or mitomycin C) prior to entering the study
COHORT : HORMONE RECEPTOR POSITIVE BREAST CANCER: Patients who have received chemotherapy in the previous  weeks ( weeks for nitrosoureas or mitomycin); other investigational agents within  weeks or a PD/PDL agent within  weeks prior to first dose of study treatment
COHORT : TRIPLE NEGATIVE BREAST CANCER: Patients who have received chemotherapy in the previous  weeks ( weeks for nitrosoureas or mitomycin); other investigational agents within  weeks or a PD/PDL agent within  weeks prior to study enrollment
COHORT : ENDOMETRIAL CANCER: Patients who have received chemotherapy in the previous  weeks ( weeks for nitrosoureas or mitomycin); other investigational agents within  weeks or a PD/PDL agent within  weeks prior to study enrollment
Subjects who have had chemotherapy or radiotherapy within  weeks ( weeks for immunotherapy;  weeks for nitrosoureas or mitomycin C) prior to starting the study agent.
Patients who have received chemotherapy in the previous  weeks ( weeks for nitrosoureas or mitomycin)
Treatment with chemotherapy or other investigational agents within  days (or at least  x the half-life of the drug) prior to day  cycle  of Minnelide ( weeks for nitrosoureas or Mitomycin C).
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) or at least  half-lives, whichever is longer, prior to entering the study
mCRPC EXPANSION COHORT: The patient has received chemotherapy, radiotherapy, biologic agents or enzalutamide within  weeks before the first dose of study treatment (nitrosoureas or mitomycin within  weeks); however, for patients receiving abiraterone, they must discontinue the medication at least  days before the first dose of study treatment
Patient who has had systemic therapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to study entry
Patients will be excluded if they have received previous chemotherapy, immunotherapy, radiotherapy or any other investigational therapy within  weeks ( weeks for nitrosoureas or mitomycin C) or  half-lives for targeted therapies prior to this study entry.
Patients who have had prior chemotherapy or any other investigational drug within  days of registration or prior radiotherapy to the study treatment volume; prior surgery is allowed; there must be at least  weeks between mitomycin or nitrosoureas and any new therapy
Have received chemotherapy <  days prior to CD, or <  days for mitomycin or nitrosoureas;
PHASE I STUDY ELIGIBILITY CRITERIA:\r\nPatients who have received chemotherapy, radiotherapy, any other investigational agents within  weeks ( weeks for nitrosoureas or mitomycin) prior to study enrollment
PHASE II STUDY COHORT  TRIPLE NEGATIVE BREAST CANCER ELIGIBILITY CRITERIA (MEDI+O ONLY):\r\nPatients who have received chemotherapy in the previous  weeks ( weeks for nitrosoureas or mitomycin); or who received radiotherapy or any other investigational agents within  weeks prior to study enrollment
PHASE II COLORECTAL CANCER COHORT  (MEDI+C ONLY):\r\nPatients who have received chemotherapy, radiotherapy, any other investigational agents within  weeks ( weeks for nitrosoureas or mitomycin) prior to study enrollment
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study; for investigational targeted therapies, patients will need to clear for  half-lives (not applicable to standard of care therapies)
Patients will be excluded if they have received previous chemotherapy, immunotherapy, radiotherapy or any other investigational therapy within  weeks ( weeks for nitrosoureas or mitomycin C) or  half-lives for non-cytotoxic agents prior to this study entry.
Chemotherapy: Chemotherapy within  weeks of PV- administration ( weeks for nitrosoureas or mitomycin C). Subjects with HCC who have been on a stable dose of sorafenib for at least  weeks will be candidates for enrollment in Expansion Cohort
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or systemic mitomycin C) before the initiation of study treatment
Ongoing or previous anti-cancer treatment within  weeks of study treatment start (or  weeks for mitomycin C, nitrosoureas and monoclonal antibodies); with exceptions.
Patient who has had systemic therapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to study entry
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study; treatment with hydroxyurea is permitted during cycle  to maintain white blood cell (WBC) < ,/uL
Chemotherapy or dose of other potentially myelosuppressive treatment within  weeks prior to Screening ( weeks for nitrosoureas or mitomycin C)
Prior chemotherapy within the last  weeks (last  weeks for nitrosoureas/mitomycin)
Patients must be >=  weeks from last chemotherapy or radiation ( weeks for nitrosoureas or mitomycin)
Patients who have had chemotherapy, radiation therapy, or other investigational agents within  weeks prior to entering study,  weeks for nitrosoureas or mitomycin
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study; hydroxyurea may be administered for count control both pre-treatment and during cycle  only
Patients must be at least  weeks from any prior systemic therapy ( weeks for nitrosoureas or mitomycin C), surgery or radiation
Patient must have recovered from toxicity of prior chemotherapy, molecularly targeted agents and/or radiotherapy; patient may not have received chemotherapy in the prior  weeks ( weeks for nitrosoureas or mitomycin C); patients may have not received a molecularly targeted agent within the past  weeks or  half lives (which ever is less); patients may not have received radiotherapy in the prior  weeks
Patients must not have received nitrosoureas or mitomycin-C within  days prior to sub-study registration
Prior chemotherapy is allowed; patients must not have received chemotherapy for  weeks prior to the initiation of study treatment and must have full recovery from any acute effects of any prior chemotherapy; patients must not have had nitrosoureas or mitomycin C for  weeks prior to the initiation of study treatment
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study
Systemic anticancer therapy within  weeks of study entry, except for nitrosoureas or mitomycin C ( weeks).
Patients must have >=  weeks since prior chemotherapy or radiation (>=  weeks for nitrosoureas or mitomycin C)
Patient who has had systemic therapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to study entry
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study
Any antitumor systemic cytotoxic therapies within  days prior to enrollment ( weeks for nitrosoureas or mitomycin-C); prior high-dose chemotherapy with bone marrow or stem cell transplant is excluded
Patients must be off radiation therapy or chemotherapy  weeks ( weeks for nitrosoureas or mitomycin C) of starting induction chemotherapy
Subjects who have had cytotoxic chemotherapy or treatment with monoclonal antibodies within  weeks ( weeks for nitrosoureas or mitomycin C), radiotherapy within  weeks, or other molecular targeted therapies (including tyrosine kinase inhibitors within  weeks prior to entering the study)
Conventional cytotoxic chemotherapy: ? weeks (?  weeks for nitrosoureas and mitomycin-C)
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study; patients who have had prior onalespib or ATM as a monotherapy will not be excluded
No chemotherapy within  weeks prior to study treatment administration; nitrosoureas and mitomycin C are not allowed within  weeks prior to initiation of study treatment
Patients should not have received any chemotherapy or investigational agents for at least  weeks before entering the study ( weeks for nitrosoureas or mitomycin C)
<  weeks for mitomycin-C or nitrosoureas
Receipt of cytotoxic chemotherapy within  weeks ( weeks for nitrosoureas and mitomycin C) of scheduled dosing day .
Prior therapy with nitrosoureas or mitomycin within  weeks prior to the first dose of TKM-.
mitomycin-C or nitrosoureas within  days
Radiotherapy (except for palliative reasons), chemotherapy, endocrine therapy, or immunotherapy during the previous  weeks ( weeks for investigational medicinal products and  weeks for nitrosoureas and Mitomycin-C) before treatment.
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study
Exposure to nitrosoureas or mitomycin C within  days before the first dose of study drug.
Previous anti-cancer therapy for malignancy within  weeks ( weeks for the nitrosoureas or mitomycin C) before day 
Treatment with radiotherapy, chemotherapy or investigational therapy within  month (or  half lifes for cytotoxics) prior to study entry ( weeks for nitrosoureas or Mitomycin C).
Received radiation therapy, surgery, or chemotherapy within  weeks prior to study entry ( weeks for nitrosoureas or Mitomycin C)
Chemotherapy or other systemic cancer therapy within  weeks of initial study treatment ( weeks for nitrosoureas or mitomycin), or regional chemotherapy (limb infusion or perfusion) within  weeks of initial study treatment
Had chemotherapy or radiotherapy within  weeks (or  weeks for nitrosoureas or mitomycin C) prior to administration of the first dose of study treatment.
Cytotoxic chemotherapy: ? the duration of the cycle of the most recent treatment regimen (a minimum of  weeks for all regimens, except  weeks for nitrosoureas and mitomycin-C).
Immunotherapy, radiotherapy, or chemotherapy ?  weeks prior to enrollment. (?  weeks for nitrosoureas, mitomycin-C, and liposomal doxorubicin, and ?  weeks from prior antibody therapy).
Patients who have had chemotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study
Have received chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to initiating administration of the study drugs
Patients who have had chemotherapy or targeted small molecule therapy within  weeks ( weeks for nitrosoureas or mitomycin C) before entering the study
Prior chemotherapy is allowed; patients must not have received chemotherapy for  weeks prior to the initiation of study treatment and must have full recovery from any acute effects of any prior chemotherapy; patients must not have had nitrosoureas or mitomycin C for  weeks prior to the initiation of study treatment
Participants who have had chemotherapy, radiotherapy, biological therapy, immunotherapy or other anticancer agents within  days (six weeks for nitrosoureas or mitomycin C) prior to entering the study
The patient has received chemotherapy or radiotherapy within  weeks or has received nitrosoureas or mitomycin C within  weeks prior to the first dose of study drug.
